Drug Absorption and Bioavailability

Introduction

Drug absorption refers to the movement of a pharmaceutical compound from the site of administration into the systemic circulation. Bioavailability is defined as the fraction of an administered dose that reaches the bloodstream unchanged and is thus available for pharmacologic action. These concepts represent a core tenet of pharmacokinetics, influencing dose selection, therapeutic efficacy, and safety profiles across all therapeutic areas.

Historically, the study of absorption emerged in the early twentieth century with the advent of plasma concentration–time profiling and the development of the first in vitro dissolution tests. Early pioneers recognized that the route of drug delivery, physicochemical properties, and biological barriers collectively determine the extent and rate at which a drug becomes systemically available. Subsequent advances in analytical techniques, in vitro–in vivo correlation (IVIVC) models, and computational pharmacokinetics have refined the understanding of absorption mechanisms and enabled rational drug design.

Grasping the principles of absorption and bioavailability is indispensable for clinicians and pharmacists. It informs therapeutic drug monitoring, anticipates drug–drug interactions, and guides formulation strategies to optimize therapeutic outcomes and minimize adverse events.

• Define drug absorption and bioavailability and distinguish between them.
• Identify the physicochemical and biological determinants that influence absorption.
• Apply mathematical models to predict absorption kinetics.
• Recognize the clinical implications of variable bioavailability in therapeutic decision‑making.
• Integrate absorption principles into formulation development and therapeutic monitoring.

Fundamental Principles

Core Concepts and Definitions

Absorption is the process by which a drug passes across a biological membrane and enters the systemic circulation. Bioavailability (F) is calculated as:

F = (AUC_administered / Dose_administered) / (AUC_reference / Dose_reference)

where AUC denotes area under the plasma concentration–time curve. For intravenous (IV) administration, F is set to 1 (or 100 %) because the drug is delivered directly into the bloodstream. For extravascular routes, F is typically <1 due to incomplete absorption or first‑pass metabolism.

Theoretical Foundations

Absorption is governed by the interplay of passive diffusion, active transport, paracellular transport, and lymphatic uptake. The rank‑order of permeability for passive diffusion follows the Lipinski “rule of five” guidelines: molecules with lower molecular weight (<500 Da), fewer hydrogen bond donors (<5), and moderate lipophilicity (log P 1–3) exhibit favorable permeability across biological membranes.

First‑pass metabolism, primarily hepatic but also intestinal, reduces systemic exposure. The extent of this effect depends on the intrinsic clearance of the drug by drug‑metabolizing enzymes (e.g., cytochrome P450 isoforms) and the rate of blood flow across the organ.

Key Terminology

• Permeability (P) – rate at which a drug crosses a membrane (cm/s).
• Surface Area (A) – absorptive surface (cm²).
• Transit Time (t) – duration the drug remains in contact with the absorptive surface (h).
• First‑Pass Extraction Ratio (E) – fraction of drug removed during first pass (0–1).
• Lag Time (t_lag) – delay before measurable absorption commences (h).
• Zero‑Order vs. First‑Order Kinetics – constant rate versus concentration‑dependent rate of absorption.

Detailed Explanation

Mechanisms and Processes

Drug absorption can be classified into several mechanisms:

1. Passive Transcellular Diffusion – the predominant route for lipophilic molecules; driven by concentration gradients across cell membranes.
2. Passive Paracellular Transport – movement between epithelial cells; limited by tight junctions, generally favors small, hydrophilic molecules.
3. Active Transport – mediated by influx and efflux transporters (e.g., P-glycoprotein, BCRP, OATP); can enhance or limit absorption.
4. Lymphatic Uptake – critical for highly lipophilic or large molecules (e.g., monoclonal antibodies); bypasses hepatic first‑pass metabolism.

Following entry into the enterocytes, drugs may undergo metabolism by intestinal enzymes (e.g., CYP3A4, UGTs), which reduces the amount reaching systemic circulation. The intestinal epithelium’s high expression of efflux transporters can further limit absorption by pumping drugs back into the lumen.

Mathematical Relationships and Models

For oral dosing, the classical absorption model is the “two‑compartment model” describing absorption (k_a), distribution, elimination (k_e), and central compartment dynamics. The plasma concentration (C_t) at time t after a single oral dose (D) can be expressed as:

C_t = (F·D·k_a / V_d(k_a – k_e)) · (e^-k_et – e^-k_at)

where V_d is the apparent volume of distribution. This equation highlights how the absorption rate constant (k_a) and the elimination rate constant (k_e) shape the concentration–time profile. In cases of saturable transport, Michaelis–Menten kinetics may be applied, replacing k_a with a function of C_t and V_max.

Factors Affecting Absorption

Absorption is influenced by a multitude of drug‐specific, patient‐specific, and formulation‐related variables:

• Physicochemical Properties – Molecular weight, lipophilicity, ionization (pKa), solubility, and crystalline form.
• Drug–Drug Interactions – Inhibition or induction of transporters and metabolizing enzymes.
• Food Effect – Food can alter gastric pH, motility, and stimulate bile secretion, affecting solubility and permeability.
• Gastrointestinal (GI) Pathophysiology – Motility disorders, mucosal integrity, pH variations, and intestinal flora composition.
• Formulation Attributes – Particle size, excipient selection, release mechanisms (immediate, sustained, enteric), and coating technologies.
• Patient Factors – Age, sex, genetics (e.g., polymorphisms in CYP enzymes), comorbidities, and concurrent medications.

Lag Time and Saturation

Lag time (t_lag) can occur when a drug requires dissolution before absorption or when transporters demonstrate a threshold concentration before activation. Saturable absorption may lead to nonlinear pharmacokinetics, especially at higher doses, as the transporter capacity becomes limiting.

Clinical Significance

Variability in absorption and bioavailability directly impacts therapeutic efficacy and safety. For drugs with narrow therapeutic indices (e.g., warfarin, phenytoin), even modest changes in bioavailability can precipitate subtherapeutic effects or toxicity. Understanding absorption mechanisms is therefore essential for dose adjustments, therapeutic drug monitoring, and anticipating drug–drug interactions.

Relevance to Drug Therapy

• Dose Optimization – Accurate estimation of F allows for precise dosing, reducing the risk of overdose or underdosing.
• Formulation Development – Enhancing bioavailability through prodrugs, nanoparticle carriers, or permeation enhancers can improve patient compliance and therapeutic outcomes.
• Personalized Medicine – Genotyping for transporter polymorphisms (e.g., SLCO1B1) can inform individualized dosing strategies.

Practical Applications

1. **Drug‑Drug Interaction Assessments** – Co‑administration of P‑glycoprotein inhibitors (e.g., verapamil) can increase bioavailability of substrate drugs (e.g., digoxin). Conversely, inducers (e.g., rifampin) may decrease it.

2. **Food‑Drug Interaction Counseling** – Some drugs (e.g., atazanavir) require administration on an empty stomach to maximize absorption, whereas others (e.g., ketoconazole) are better absorbed with food.

3. **Monitoring of Oral Anticoagulants** – Dabigatran’s bioavailability is affected by gastric pH and proton pump inhibitors; clinicians may consider alternate agents or dosage adjustments.

Clinical Applications/Examples

Case Scenario 1: Variable Bioavailability of an Oral Antidiabetic

A 58‑year‑old woman with type 2 diabetes is prescribed glipizide. After two weeks, her fasting blood glucose remains high despite adherence. The clinician suspects reduced bioavailability due to a newly diagnosed gastric ulcer leading to altered gastric pH and delayed gastric emptying. Switching to a once‑daily dose of metformin, which has a higher permeability and is less affected by gastric pH, results in improved glycemic control.

Case Scenario 2: First‑Pass Metabolism of a New Antiviral

An investigational oral antiviral exhibits a preclinical oral bioavailability of 15 %. In vitro studies reveal extensive CYP3A4 metabolism in the intestinal mucosa. Co‑administration with a mild CYP3A4 inhibitor (e.g., itraconazole) elevates systemic exposure by approximately 4‑fold, enabling a dose reduction and potentially reducing renal toxicity.

Problem‑Solving Approach for Low Bioavailability Drugs

1. Identify the limiting factor: solubility, permeability, or first‑pass metabolism.
2. Assess the drug’s physicochemical properties and transporter interactions.
3. Explore formulation strategies: micronization, solid dispersions, lipid-based systems, or prodrugs.
4. Consider alternate routes of administration (e.g., sublingual, transdermal) to bypass first‑pass effects.
5. Validate improvements via in vitro dissolution, permeability assays, and IVIVC studies.

Summary / Key Points

• Drug absorption is the movement from the site of administration into systemic circulation; bioavailability is the fraction that remains unchanged in the bloodstream.
• Passive diffusion, active transport, paracellular pathways, and lymphatic uptake constitute the principal mechanisms of absorption.
• Key determinants of absorption include molecular weight, lipophilicity, ionization, permeability, and the presence of transporters or metabolic enzymes.
• Mathematical models such as the two‑compartment model and Michaelis–Menten kinetics enable prediction of absorption profiles and inform dose selection.
• Factors such as food, GI physiology, drug interactions, and formulation attributes can markedly alter absorption and bioavailability.
• Clinically, variability in bioavailability necessitates dose adjustments, therapeutic drug monitoring, and careful consideration of drug–drug and food interactions.
• Strategies to enhance bioavailability encompass formulation modifications, transporter modulation, and alternative routes of administration.

Mastery of drug absorption and bioavailability principles equips clinicians and pharmacists to optimize therapeutic regimens, mitigate adverse events, and contribute to the rational development of new pharmaceutical products.

References

1. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Philadelphia: Wolters Kluwer; 2011.
2. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 7th ed. New York: McGraw-Hill Education; 2016.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.